埼玉パチスロ優良店 Release

Top
埼玉パチスロ優良店

Latest 埼玉パチスロ優良店

November 2, 2020: Revision of Consolidated Financial Forecasts
October 12, 2020: 埼玉パチスロ優良店 assigns Intellectual Properties regarding KRP-203 to Priothera
September 30, 2020: Notice regarding the joint development and commercialization agreement for [AKP-009], a treatment agent for Benign Prostatic Hyperplasia
August 3, 2020: First Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2021 - Supplementary Information
August 3, 2020: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the First Quarter Ending Dec 31, 2021) [Japanese Standard]
August 3, 2020: 埼玉パチスロ優良店 and Otonomy Signed License Agreement for Novel Candidate Compound for Sensorineural Hearing Loss
June 29, 2020: 埼玉パチスロ優良店 Pharmaceutical obtains approval for additional indication for pediatric use of Flutiform® 50 Aerosol, a combination drug for asthma treatment
May 12, 2020: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the fiscal year ended March 31, 2020) [Japanese Standard]
May 12, 2020: Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2020- Supplementary Information
March 31, 2020: Release of Novel Coronavirus Detection Reagent "SARS-CoV-2 GeneSoC ER 埼玉パチスロ優良店"
February 5, 2020: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the Third Quarter Ended Dec 31, 2019) [Japanese Standard]
February 5, 2020: Third Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2020 - Supplementary Information
January 6, 2020: 埼玉パチスロ優良店 and aTyr to Collaborate on Novel Immunomodulator
November 19, 2019: NHI Drug Price Listing and Release of Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
November 7, 2019: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the Second Quarter Ended September 30, 2019) [Japanese Standard]
November 7, 2019: Second Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2020 - Supplementary Information
November 7, 2019: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020
November 7, 2019: Absorption-type Merger between the Consolidated Subsidiaries
November 7, 2019: 埼玉パチスロ優良店 and JEIL Signed License Agreement for Vibegron in Korea
November 5, 2019: Revision of Consolidated Financial Forecasts
October 29, 2019: Release of Microchannel-based Genetic Measurement Device GeneSoC®
October 28, 2019: Resumption of Supply of Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
September 20, 2019: 埼玉パチスロ優良店 Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent "Lasvic®Tablets 75mg"
August 23, 2019: Release of Mometasone Nasal 50μg「埼玉パチスロ優良店」56sprays, 112sprays
July 31, 2019: Summary of Consolidated Financial 埼玉パチスロ優良店(July 31,2019)
July 31, 2019: First Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2020
May 14, 2019: Financial 埼玉パチスロ優良店 for Fiscal 2018
May 13, 2019: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the fiscal year ended March 31, 2019) [Japanese Standard]
May 13, 2019: Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2019
May 13, 2019: 埼玉パチスロ優良店 Signed Memorandum of Understanding on Marketing Collaboration with respect to Chronic Cough Treatment
April 2, 2019: Release of Alcohol-Free Hand Sanitizer Noahtect® Pro
March 27, 2019: Conclusion of Agreement on OTC Drug Marketing Rights with DER UAW PHARMACEUTICAL 埼玉パチスロ優良店., LTD.
March 27, 2019: Conclusion of Agreement with Monospharm Trade 埼玉パチスロ優良店., Ltd. Concerning Marketing Rights for Generic Medicines
February 5, 2019: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the Third Quarter Ended Dec 31, 2018) [Japanese Standard]
February 5, 2019: Third Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2019 - Supplementary Information
February 5, 2019: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
January 7, 2019: Impact on 埼玉パチスロ優良店's Financial Performance of MSD's Decision to Voluntarily Recall Desalex® Tablets 5mg Long-Acting Selective H1 Receptor Antagonist for Allergic Diseases Treatment
December 27, 2018: Hebrew University to Collaborate with 埼玉パチスロ優良店 Strategic partnership aims to develop respiratory drug therapies
November 20, 2018: Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
November 5, 2018: Summary of Consolidated Financial 埼玉パチスロ優良店 (For the Second Quarter Ended September 30, 2018) [Japanese Standard]
November 5, 2018: Second Quarter Consolidated Financial 埼玉パチスロ優良店 for the Fiscal Year Ending March 31, 2019
November 5, 2018: Notice Regarding the Cancellation of Treasury Stock
November 2, 2018: Revision of Consolidated Financial Forecasts
September 27, 2018: Notice on 埼玉パチスロ優良店 and Completion of Acquisition of Treasury Stock through Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3) and Change to Major Shareholder
September 26, 2018: Notice of Acquisition of Treasury Stock and Purchase of Treasury Stock by Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3)
September 21, 2018: 埼玉パチスロ優良店 Receives Marketing Approval in Japan for｢Beova Tablets 50mg｣ for the Treatment of Overactive Bladder
August 6, 2018: (Corrections: Corrections of Numeric Data) On the Partial Correction of the Summary Accounts of the First Quarter of the Business Year Ending in March 2019 [Japanese Standard] (Consolidated)
August 1, 2018: 埼玉パチスロ優良店 Pharmaceutical and FAES Farma Sign Agreement on Development and Distribution of Imidafenacin in Latin America
July 31, 2018: Summary of Consolidated Financial 埼玉パチスロ優良店（July 31, 2018)
July 31, 2018: Supplementary information (July 31, 2018)